Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445362 | 0.91 | CFTR (0.64) | CFTR | |
| SCHEMBL16445147 | 0.89 | CFTR (0.61) | CFTR | |
| SCHEMBL16445440 | 0.88 | CFTR (0.66) | CFTR | |
| SCHEMBL16451344 | 0.87 | CFTR (0.52) | CFTR | |
| SCHEMBL16445570 | 0.86 | CFTR (0.64) | CFTR | |
| SCHEMBL16445501 | 0.83 | CFTR (0.69) | CFTR | |
| SCHEMBL16446021 | 0.82 | CFTR (0.70) | CFTR | |
| SCHEMBL16445860 | 0.82 | CFTR (0.68) | CFTR | |
| SCHEMBL16445799 | 0.81 | CFTR (0.62) | CFTR | |
| SCHEMBL16450559 | 0.81 | CFTR (0.66) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | claimed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | claimed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | claimed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | claimed |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-02-21 | — | — | US | claimed |
| EP-3030568-B1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2018-09-19 | — | — | EP | claimed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | claimed |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | GALAPAGOS SASU (FR) | 2018-04-19 | — | — | US | claimed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | claimed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | claimed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | claimed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | claimed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | claimed |
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL ENTPR LTD (BM) | 2024-02-08 | — | — | US | disclosed |
| US-20220281857-A1 | Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL ENTPR LTD (BM) | 2022-09-08 | — | — | US | disclosed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | CFTR, ABCB11, PKD1 | CFTR 1/4885 |
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SLC47A2 | CFTR 1/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20220281857-A1 | Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A2, SLC47A1 | CFTR 1/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885 |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | CFTR, P2RX2, P2RX1 | CFTR 1/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, P2RY1, P2RX5 | CFTR 1/4885 |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.